Immunogenicity of human cardiac valve allografts

E. Simon,N. Zavazava,G. Steinhoff,W. Müller-Ruchholtz,A. Haverich

DOI: https://doi.org/10.1007/978-3-642-59250-8_10

1997-01-01

Abstract:Since the use of human cadaver tissue was introduced into clinical practice by Gross in 1948 (5), the implantation or transplantation of allogeneic tissue has become an accepted treatment of organ and tissue failure. Lam et al. introduced the concept of allograft heart valve replacement in 1952 (9). Today, the use of allogeneic material for heart valve replacement is an accepted clinical treatment option along with mechanical valve prostheses, which have a better long-term function but require anticoagulation. Also, xenogeneic valve replacements are now widely used, the newest development being stentless xeno-valve prostheses. The two main preclusions to the use of the allograft valve are principally the same as they were in the beginning: Firstly, the complex technique of implantation in the aortic or mitral position and secondly, the limited long-term function of the prosthesis (3). After implantation, allograft valves undergo a process of degeneration, which ultimately leads to their destruction. The factors contributing to this phenomenon are still not clearly understood. While the administration of immunosuppressive drugs is the standard therapy for recipients of whole organs (heart, lung, liver, kidney) and other viable tissues such as pancreatic islet cells and corneas, this concept has not been accepted in the field of allograft valve transplantation. Indeed, it was commonly assumed that no relevant immunological reactions could be triggered by the graft. However, there is growing evidence that, in spite of the widespread belief that “we are implanting dead meat” (D. Ross), there is indeed a very relevant impact of immunological factors in the degeneration of allograft heart valve prostheses.